GENE ONLINE|News &
HebaBiz Biotech Obtains FDA Clearance to Trial Cancer Drug Against Aggressive Brain Tumor
Glioblastoma (GBM) is the most common and aggressive form of brain tumor with a poor prognosis. Existing treatment includes surgery, followed by radiotherapy, and chemotherapy. Yet, several patients develop resistance to treatments, suffer from relapse, and die, creating a significant unmet need in this area.
At this juncture, Beijing-based HebaBiz Biotech announces that the FDA has accepted IND for its innovative anti-cancer drug for Glioblastoma trials in the US.
At this juncture, Beijing-based HebaBiz Biotech announces that the FDA has accepted IND for its innovative anti-cancer drug for Glioblastoma trials in the US.
GO Prime with only $1.49 now
LATEST
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
